Selected research
Market Analysis & Forecast
Global Kidney Cancer Market Analysis and Forecast 2026-2032
Market perspective
The global Kidney Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Kidney Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Kidney Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Kidney Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Kidney Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Kidney Cancer include Aveo Pharmaceuticals, Bristol-Myers Squibb, Exelixis, Hikma Pharmaceuticals, Sun Pharmaceutical, Amgen, Bayer, Pfizer and Roche, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Kidney Cancer, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Kidney Cancer, also provides the revenue of main regions and countries. Of the upcoming market potential for Kidney Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Kidney Cancer revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Kidney Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Kidney Cancer revenue, projected growth trends, production technology, application and end-user industry.
Kidney Cancer Segment by Company
Aveo Pharmaceuticals
Bristol-Myers Squibb
Exelixis
Hikma Pharmaceuticals
Sun Pharmaceutical
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Eisai
Kidney Cancer Segment by Type
Targeted Therapy
Immunotherapy
Surgery
Other
Kidney Cancer Segment by Application
Renal Cell Carcinoma
Renal Pelvis Cancer
Other
Kidney Cancer Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Kidney Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Kidney Cancer company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Cancer revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Therapy
- Immunotherapy
- Surgery
- Other
Applications
- Renal Cell Carcinoma
- Renal Pelvis Cancer
- Other
Companies covered
- Aveo Pharmaceuticals
- Bristol-Myers Squibb
- Exelixis
- Hikma Pharmaceuticals
- Sun Pharmaceutical
- Amgen
- Bayer
- Pfizer
- Roche
- Merck
- Novartis
- Eisai
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Kidney Cancer Market by Type
- 1.2.1 Global Kidney Cancer Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Targeted Therapy
- 1.2.3 Immunotherapy
- 1.2.4 Surgery
- 1.2.5 Other
- 1.3 Kidney Cancer Market by Application
- 1.3.1 Global Kidney Cancer Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Renal Cell Carcinoma
- 1.3.3 Renal Pelvis Cancer
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Kidney Cancer Market Dynamics
- 2.1 Kidney Cancer Industry Trends
- 2.2 Kidney Cancer Industry Drivers
- 2.3 Kidney Cancer Industry Opportunities and Challenges
- 2.4 Kidney Cancer Industry Restraints
3 Global Growth Perspective
- 3.1 Global Kidney Cancer Market Perspective (2021-2032)
- 3.2 Global Kidney Cancer Growth Trends by Region
- 3.2.1 Global Kidney Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Kidney Cancer Market Size by Region (2021-2026)
- 3.2.3 Global Kidney Cancer Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Kidney Cancer Revenue by Players
- 4.1.1 Global Kidney Cancer Revenue by Players (2021-2026)
- 4.1.2 Global Kidney Cancer Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Kidney Cancer Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Kidney Cancer Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Kidney Cancer Key Players Headquarters & Area Served
- 4.4 Global Kidney Cancer Players, Product Type & Application
- 4.5 Global Kidney Cancer Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Kidney Cancer Market CR5 and HHI
- 4.6.3 2025 Kidney Cancer Tier 1, Tier 2, and Tier 3
5 Kidney Cancer Market Size by Type
- 5.1 Global Kidney Cancer Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Kidney Cancer Revenue by Type (2021-2032)
- 5.3 Global Kidney Cancer Revenue Market Share by Type (2021-2032)
6 Kidney Cancer Market Size by Application
- 6.1 Global Kidney Cancer Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Kidney Cancer Revenue by Application (2021-2032)
- 6.3 Global Kidney Cancer Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Aveo Pharmaceuticals
- 7.1.1 Aveo Pharmaceuticals Company Information
- 7.1.2 Aveo Pharmaceuticals Business Overview
- 7.1.3 Aveo Pharmaceuticals Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.1.4 Aveo Pharmaceuticals Kidney Cancer Product Portfolio
- 7.1.5 Aveo Pharmaceuticals Recent Developments
- 7.2 Bristol-Myers Squibb
- 7.2.1 Bristol-Myers Squibb Company Information
- 7.2.2 Bristol-Myers Squibb Business Overview
- 7.2.3 Bristol-Myers Squibb Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.2.4 Bristol-Myers Squibb Kidney Cancer Product Portfolio
- 7.2.5 Bristol-Myers Squibb Recent Developments
- 7.3 Exelixis
- 7.3.1 Exelixis Company Information
- 7.3.2 Exelixis Business Overview
- 7.3.3 Exelixis Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.3.4 Exelixis Kidney Cancer Product Portfolio
- 7.3.5 Exelixis Recent Developments
- 7.4 Hikma Pharmaceuticals
- 7.4.1 Hikma Pharmaceuticals Company Information
- 7.4.2 Hikma Pharmaceuticals Business Overview
- 7.4.3 Hikma Pharmaceuticals Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.4.4 Hikma Pharmaceuticals Kidney Cancer Product Portfolio
- 7.4.5 Hikma Pharmaceuticals Recent Developments
- 7.5 Sun Pharmaceutical
- 7.5.1 Sun Pharmaceutical Company Information
- 7.5.2 Sun Pharmaceutical Business Overview
- 7.5.3 Sun Pharmaceutical Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.5.4 Sun Pharmaceutical Kidney Cancer Product Portfolio
- 7.5.5 Sun Pharmaceutical Recent Developments
- 7.6 Amgen
- 7.6.1 Amgen Company Information
- 7.6.2 Amgen Business Overview
- 7.6.3 Amgen Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.6.4 Amgen Kidney Cancer Product Portfolio
- 7.6.5 Amgen Recent Developments
- 7.7 Bayer
- 7.7.1 Bayer Company Information
- 7.7.2 Bayer Business Overview
- 7.7.3 Bayer Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.7.4 Bayer Kidney Cancer Product Portfolio
- 7.7.5 Bayer Recent Developments
- 7.8 Pfizer
- 7.8.1 Pfizer Company Information
- 7.8.2 Pfizer Business Overview
- 7.8.3 Pfizer Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.8.4 Pfizer Kidney Cancer Product Portfolio
- 7.8.5 Pfizer Recent Developments
- 7.9 Roche
- 7.9.1 Roche Company Information
- 7.9.2 Roche Business Overview
- 7.9.3 Roche Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.9.4 Roche Kidney Cancer Product Portfolio
- 7.9.5 Roche Recent Developments
- 7.10 Merck
- 7.10.1 Merck Company Information
- 7.10.2 Merck Business Overview
- 7.10.3 Merck Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.10.4 Merck Kidney Cancer Product Portfolio
- 7.10.5 Merck Recent Developments
- 7.11 Novartis
- 7.11.1 Novartis Company Information
- 7.11.2 Novartis Business Overview
- 7.11.3 Novartis Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.11.4 Novartis Kidney Cancer Product Portfolio
- 7.11.5 Novartis Recent Developments
- 7.12 Eisai
- 7.12.1 Eisai Company Information
- 7.12.2 Eisai Business Overview
- 7.12.3 Eisai Kidney Cancer Revenue and Gross Margin (2021-2026)
- 7.12.4 Eisai Kidney Cancer Product Portfolio
- 7.12.5 Eisai Recent Developments
8 North America
- 8.1 North America Kidney Cancer Revenue (2021-2032)
- 8.2 North America Kidney Cancer Revenue by Type (2021-2032)
- 8.2.1 North America Kidney Cancer Revenue by Type (2021-2026)
- 8.2.2 North America Kidney Cancer Revenue by Type (2027-2032)
- 8.3 North America Kidney Cancer Revenue Share by Type (2021-2032)
- 8.4 North America Kidney Cancer Revenue by Application (2021-2032)
- 8.4.1 North America Kidney Cancer Revenue by Application (2021-2026)
- 8.4.2 North America Kidney Cancer Revenue by Application (2027-2032)
- 8.5 North America Kidney Cancer Revenue Share by Application (2021-2032)
- 8.6 North America Kidney Cancer Revenue by Country
- 8.6.1 North America Kidney Cancer Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Kidney Cancer Revenue by Country (2021-2026)
- 8.6.3 North America Kidney Cancer Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Kidney Cancer Revenue (2021-2032)
- 9.2 Europe Kidney Cancer Revenue by Type (2021-2032)
- 9.2.1 Europe Kidney Cancer Revenue by Type (2021-2026)
- 9.2.2 Europe Kidney Cancer Revenue by Type (2027-2032)
- 9.3 Europe Kidney Cancer Revenue Share by Type (2021-2032)
- 9.4 Europe Kidney Cancer Revenue by Application (2021-2032)
- 9.4.1 Europe Kidney Cancer Revenue by Application (2021-2026)
- 9.4.2 Europe Kidney Cancer Revenue by Application (2027-2032)
- 9.5 Europe Kidney Cancer Revenue Share by Application (2021-2032)
- 9.6 Europe Kidney Cancer Revenue by Country
- 9.6.1 Europe Kidney Cancer Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Kidney Cancer Revenue by Country (2021-2026)
- 9.6.3 Europe Kidney Cancer Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
- 9.6.9 Nordic Countries
10 China
- 10.1 China Kidney Cancer Revenue (2021-2032)
- 10.2 China Kidney Cancer Revenue by Type (2021-2032)
- 10.2.1 China Kidney Cancer Revenue by Type (2021-2026)
- 10.2.2 China Kidney Cancer Revenue by Type (2027-2032)
- 10.3 China Kidney Cancer Revenue Share by Type (2021-2032)
- 10.4 China Kidney Cancer Revenue by Application (2021-2032)
- 10.4.1 China Kidney Cancer Revenue by Application (2021-2026)
- 10.4.2 China Kidney Cancer Revenue by Application (2027-2032)
- 10.5 China Kidney Cancer Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Kidney Cancer Revenue (2021-2032)
- 11.2 Asia Kidney Cancer Revenue by Type (2021-2032)
- 11.2.1 Asia Kidney Cancer Revenue by Type (2021-2026)
- 11.2.2 Asia Kidney Cancer Revenue by Type (2027-2032)
- 11.3 Asia Kidney Cancer Revenue Share by Type (2021-2032)
- 11.4 Asia Kidney Cancer Revenue by Application (2021-2032)
- 11.4.1 Asia Kidney Cancer Revenue by Application (2021-2026)
- 11.4.2 Asia Kidney Cancer Revenue by Application (2027-2032)
- 11.5 Asia Kidney Cancer Revenue Share by Application (2021-2032)
- 11.6 Asia Kidney Cancer Revenue by Country
- 11.6.1 Asia Kidney Cancer Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Kidney Cancer Revenue by Country (2021-2026)
- 11.6.3 Asia Kidney Cancer Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Kidney Cancer Revenue (2021-2032)
- 12.2 SAMEA Kidney Cancer Revenue by Type (2021-2032)
- 12.2.1 SAMEA Kidney Cancer Revenue by Type (2021-2026)
- 12.2.2 SAMEA Kidney Cancer Revenue by Type (2027-2032)
- 12.3 SAMEA Kidney Cancer Revenue Share by Type (2021-2032)
- 12.4 SAMEA Kidney Cancer Revenue by Application (2021-2032)
- 12.4.1 SAMEA Kidney Cancer Revenue by Application (2021-2026)
- 12.4.2 SAMEA Kidney Cancer Revenue by Application (2027-2032)
- 12.5 SAMEA Kidney Cancer Revenue Share by Application (2021-2032)
- 12.6 SAMEA Kidney Cancer Revenue by Country
- 12.6.1 SAMEA Kidney Cancer Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Kidney Cancer Revenue by Country (2021-2026)
- 12.6.3 SAMEA Kidney Cancer Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst